Volume 4 | Issue 2 | 2017-11-14

Gene Polymorphisms of Cytokines IFN γ +874 (A/T), TNF Α -308 (G/A), IL-6 -174 (G/C), L’il-10 -1082 (A/G), -819 (C/T) -592 (C/A), TGF-β1 +869 (T /C), +915 (G/C) in Algerian Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA)

Rachida Raache

Abstract

Background: We aimed to investigate the association between five cytokines (IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 (G/C), L il-10 -1082 (A/G), -819 (C/T) -592 (C/A), TGF- 1 +869 (T /C), +915 (G/C) and patients with type 1 diabetes (T1D) and Latent Autoimmune Diabetes in Adults (LADA). Methods: Polymorphisms of cytokine were determined using the Sequence Specific Primers method (PCR-SSP) in 50 patients and 74 controls. Results: The results showed significantly higher frequency of IFN +874 TA genotype (65.38% vs. 45.95%, pc = 0.046) in T1D vs. controls. While T allele (56.25% vs. 35.14%) in LADA vs. controls. While significantly higher frequency of TNF ( -308 G/A) A allele (26.92% vs. 13.51%) in T1D vs. controls and significantly higher frequency of GA Genotype (41.6% vs. 24.32%) in LADA vs. controls. While the results showed significantly higher frequency of IL-10 -1082 A/G) G/A genotype (65. 38% vs. 45.95) in T1D and LADA versus control and IL-10 -592 (C/A) C allele (84% vs. 68.92%) Regarding polymorphisms of IL-6 no significant difference was observed between T1D, LADA and controls. Conclusion: These results suggest that the secretion low of IFN- and high secretion of TNF- may play an important role in protection and susceptibility to autoimmune diabetes in the Algerian population.

Keywords: Type 1 Diabetes, Polymorphisms, Latent Autoimmune Diabetes

Full text

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by absolute insulin deficiency resulting from the progressive immune-mediated destruction of pancreatic islet cells [1,2] . Genetic factor influence both susceptibility and resistance to the disease. More than 20 loci involved in susceptibility to type 1 diabetes have been described among them IDDM1 (Major histocompatibility Complexe-MHC) [3] , IDDM2-Insuline gene on chromosome [4] and the PTPN22 gene [5] . The patients with Latent Autoimmune Diabetes In Adults (LADA) have a progressive insulin secretion defect and have a genetic predisposition with type 1 diabetes (1) but differed phenotypically from type 1 diabetes diagnosed after age 35 years and within LADA depended on GAD antibody (GADA) levels. Multiple immune mediators are implicated in the destruction or protection of the pancreatic -cells including tumor necrosis factor (TNF ), interferon (IFN ) and IL-6. They are pro-inflammatory cytokines produced primarily by activated macrophages that infiltrate the islets during the pathogenesis of diabetes [6] and play a central role in -cell destruction [7] . In human, the IFN is encoded by four-exon gene on chromosome 12q14, also exhibits antiviral activity but in contrast to the type I interferon, its main biological activity appears to be immunomodulatory [8] . The TNF- gene is located within the highly polymorphic major histocompatibility complex region on chromosome 6p21.3 [9] . Many studies have shown that SNP at position ?308 G/A was associated with various inflammatory conditions. Polymorphism in the 50 flanking region of the IL-6 gene on chromosome 7p21 at position ?174 has been reported to exert an effect on its secretion and function [10] . Interleukin-10 (IL-10) is an anti-inflammatory cytokine with a crucial role in preventing inflammatory and autoimmune pathologies [11] . IL-10 is immunosuppressive substance produced within the body and plays a role in the regulation of immune responses [12] . The gene for IL-10 in chromosome region 1q31 q32 presents two CA-repeat microsatellites in the 50-flanking region: IL-10 R and IL-10 G, at _4 and _1.1 kb, respectively [13] . In addition, three single nucleotide polymorphisms (SNPs) in its promoter at positions -1082 (G/A), -819 (C/T) and -592 (C/A) have been identified [14] . Single nucleotide polymorphisms (SNPs) of IFN , TNF , IL-6, l IL-10, TGF- 1 may influence the expression of the coded cytokine and in this way these candidate genes may play a role in the patho-mechanism of T1DM and LADA. In our study we aimed to determine the genotype association of IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 G/C, l IL-10 -1082 A/G, -819 (C/T) -592 C/A), TGF- 1 +869 (T/C), +915 (G/C) SNP in Algerian case with type 1 diabetes in juvenile and Latent Autoimmune Diabetes in Adults. Methods Patients and Controls Blood samples were taken from 24 juveniles with T1D (18 - 35 years) and 26 LADA treated in the First service of diabetology, Mustapha University, Alger during 2010 - 2014 and 74 (18 - 35 years) of unrelated healthy individuals used as a control. Diabetic patients were diagnosed using the criteria of the National Diabetes Data Group [15] . The diagnosis of Type 1 diabetes and LADA was based on clinical data consisting of diabetic ketoacidosis, absolute insulin dependence and /or spontaneous ketoacidosis and /or severe insulinopenia and weight loss. Cytokine gene polymorphism genomic DNA was isolated from peripheral blood samples using phenol-chloroform technique [16] . 50 patients with auto immune and 75 normal healthy controls were studied for cytokine gene polymorphisms using the Polymerase chain reaction sequence specific primers (PCR-SSP). The polymorphisms analyzed were interferon- (IFN )(A +874 T), TNF (G -308 A), interleukin IL-6 (G -174 C), IL-10 (A -1082 G, T -819 C, C -592 A) and transforming growth factor TGF- 1 (T +869 C), (G +915 C) (One Lambda Canoga Park CA). All PCR amplifications were performed in 10 l reaction volumes containing 80 ng/ l of genomic DNA mixed with master mix containing 2U/ l Taq DNA polymerase. This DNA and mastermix was dispensed into 96-well trays pre-aliquoted with primers and amplified in an automated thermal cycler (9600 Perkin-Elmer Cetus, CA, USA). The PCR products were fractionated on 2% (w/v) agarose gel electrophoresis, stained with ethidium bromide (10 g/ml) and visualized under UV illumination. Each tube had an internal positive control band to check the integrity of PCR. Statistical analysis Statistical analysis was performed using the compare 2 software, version 2 (Chicago, IL, USA). Fisher s exact test was used to determine the significance of differences between the patient and the control groups. Bonferroni s correction was performed for multiple comparisons. Odds ratios were calculated using Woolf s method with Haldane modification whenever the numbers were five or less [17] table 1. Table 1: IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 G/C, l IL-10 -1082 A/G, -819 (C/T) -592 C/A), TGF- 1 +869 (T/C), +915 (G/C) genotype frequencies among cases with type 1 diabetes compared to controls with their statistical significance. Genotype/ T1D N= 26 LADA N= 24 Control N = 74 n(%) n(%) Pc OR (95%CI) n(%) Pc OR (95%CI) IFN +874 (A/T) AA 8 (30.76) 0.169 0.62 (- ) 4(16.66) 0.013 0.28 0.06 - 0.95 31(41.89) TA 17 (65.38) 0.046 2.22 0.80 - 6.39 14(58.33) 0.149 - 0.58 - 4,7 34(45.33) TT 1 (3.84) 0.153 0.29 - 6 (25) 0.062 - 0.61 - 8,72 9(12.16) TNF -308 (G/A) GG 14 (53,84) 0,027 0,40 0,14 - 1,14 14 (58,3) 0,06 0,48 - 55(74,32) GA 10 (38,46) 0,082 1,94 - 10 (41.6) 0.05 2.22 0.73 - 6.46 18(24,32) AA 2 (7,69) 0,05 6,08 0,29 - 363,6 0 / / / 1(1,35) IL-6 -174 (G/C) GG 16 (61,538) 0,105 0,55 - 19(79,1) 0,352 1,31 - 55(74,32) GC 8 (30,76) 0,243 1,38 - 5 (20,8) 0,403 0,82 - 18(24,32) CC 2 (7,69) 0,056 6,08 - 0 / / / 1(1,35) IL-10 -1082 A/G AA 7 (26.92) 0.24 0,68 5 (20,8) 0,10 0,49 - 26(35,14) GA 17 (65.38) 0.046 2 .22 - 14(58,3) 0,149 1,65 - 34(45.95) GG 2 (7.69) 0.11 0,36 - 5 (20,8) 0,376 1,13 - 14(18,92) IL-10 -819 (C/T) CC 12 (46,16) 0,46 0,96 - 16(66,6) 0,05 2,23 - 35(47,30) CT 13 (50) 0,27 1,31 - 8(33,33) 0,20 0,66 - 32(43,24) TT 1 (3,84) 0,25 0,38 - 0 / / / 7(9,46) IL-10 -592 (C/A) CC 12 (46,15) 0,46 0.86 - 16(33) 0,207 0,66 - 35(47,30) CA 13 (50) 0,27 1.31 - 8 (33) 0,207 0,66 - 32(43,24) AA 1 (3,84) 0,25 0.38 - 0 / / / 7(9,46) TGF- 1 +869 T/C TT 13 (50) 6.8 10 -3 3.35 - 8 (33,33) 0,146 1,68 - 17(22,97) TC 10 (38,46) 5.8 10 -3 0.30 - 12 (50) 0,061 0,48 - 50(67,57) CC 3 (11.53) 0.322 1.25 - 4 (16,66) 0,144 1,91 - 7(9,46) TGF- 1 +915 (G/C) GG 16(61,53) 1.310 -3 0,19 - 19 (79,1) 0,09 0,46 - 66(89,19) GC 10 38,46) 1.310 -3 5,16 - 5 (20,83) 0,09 2,17 - 8 (10,81) CC 0 / 0 0 R (95 th CI) ¼ odds ratio (95% confidence interval) NB: Results Table 2 and table 3 shows TNF, IFN , IL-6, IL10 and TGF genotype and allele distribution in our T1D, LADA population and controls. IFN +874 TA genotype was significantly more frequent in T1D patients than in the controls (65.38% vs . 45.95%, pc = 0.046, OR = 2.22) corresponding to a profile of intermediary secretion (73.07% vs . 45.95%, pc = 0.009, OR = 3.19) and T allele was significantly more frequent in LADA patients than in the controls (56.25% vs . 35.14%, pc = 0.005, OR = 2.37) corresponding to a profile of high secretion (29.16% vs . 12.16%, pc = 0.027, OR = 2.97). While A allele (64.86% vs . 43.75%, pc = 0.005, OR = 0.42) and AA genotype (41.89% vs . 16.66%, pc = 0.013, OR = 0.28) respectively were significantly more frequent in control than in LADA patient, corresponding to a profile of low secretion (41.89% vs . 16.66%, pc = 0.013, OR = 0.28). While significantly, higher frequency of TNF -308 A allele have obtained in T1D vs. Control (26.92% vs . 13.51%, P = 0,015, OR = 2.36) corresponding to a higher secretion profile (46.15% vs. 25.68%, P = 0.027, OR = 2.48) in T1D versus controls. However the results showed significantly higher frequency of TNF ( -308 G/A) GA Genotype (41.6% vs . 24.32%, P = 0.05, OR =2.22) and high secretion profile (45.83% vs . 25.68%, pc = 0.032, OR = 2.45) in LADA versus controls. However the results showed significantly higher frequencies of TNF -308 G allele 86,49% vs . 73,07%, pc = 0.015, OR = 0.42) GG genotype (74.32% vs . 53.84%, pc = 0.027, OR = 0.4) in controls versus T1D, corresponding to a profile of low secretion (53.85% vs . 74.32%, pc = 0.027, OR = 0.4). Table 2: IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 G/C, l IL-10 -1082 A/G, -819 (C/T) -592 C/A), TGF- 1 +869 (T/C), +915 (G/C) allele frequencies among cases with type 1 diabetes and LADA compared to controls with their statistical significance Alleles T1D 2N= 52 LADA 2N = 48 Control n(%) 2N = 148 n(%) Pc OR (95%CI) n(%) Pc OR (95%CI) IFN +874 (A/T) A 33 (63.46) 0.417 0.94 ( - ) 21(43,75) 5.1 10-3 0.42 0.20 - 0,86 96(64.86) T 19 (36.53) 0.417 1.06 ( - ) 27(56,25) 0 .05 2.37 1.16 - 4.87 52(35.14) TNF -308 (G/A) G 38 (73.07) 0.015 0.42 (0.18 - 1.004) 38(79,16) 0,10 0,59 - 128(86.49) A 14 (26.92) 0.015 2.36 (0.99 - 5.43) 10(20,83) 0,10 1,68 - 20(13.51) IL-6 -174 (G/C) G 40 (76,923) 0,051 0,52 (-) 43(86,5) 0,334 1,34 - 128(86,49) C 12 (23,077) 0,051 1,92 (-) 5 (10,4) 0,334 0,74 - 20(13,51) IL-10 -1082 A/G A 31 (59,61) 0,43 1,06 (-) 24(50) 0,16 0,72 - 86(58,11) G 21 (40,38) 0,43 0,94 (-) 24(50) 0,16 1,39 - 62(41,89) IL-10 -819 (C/T) C 37 (71,16) 0,39 1,11 (-) 40(83,3) 0,02 2,25 - 102(68,92) T 15 (28,84) 0,39 0,90 (-) 8 (16,6) 0,044 0,44 - 46(31,08) IL-10 -592 (C/A) C 37 (71,15) 0.39 1,11 (-) 40(84) 0.03 2.25 - 102(68.92) A 15 (28,84) 0.39 3,27 (-) 8 (16) 0.03 0. 44 - 46(31.08) TGF- 1 +869 T/C T 36 (69,23) 0,058 1,71 (-) 28(58,3) 0,43 1,07 - 84(56,7) C 16 (30,76) 0,058 0,58 (-) 20 (41,6) 0,43 1,07 - 64(43,24) TGF- 1 +915 (G/C) G 42 (80,76) 2.1 10 -3 0,24 (-) 43 (89,6) 0,09 0,49 - 140(94,59) C 10 (19,23) 2.1 10 -3 4,17 (-) 5 (10,41) 0,09 2,03 - 8(5,41) OR (95 th CI) ¼ odds ratio (95% confidence interval) Table 3: IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 G/C, l IL-10 -1082 A/G, -819 (C/T) -592 C/A), TGF- 1 +869 (T/C), +915 (G/C) Secretion profil among cases with type 1 diabetes compared to controls with their statistical significance. Secretion profile T1D N = 26 2N = 52 LADA N = 24 2N = 52 Control n(%) 2N= 148 n(%) Pc OR (95%CI) n(%) Pc OR (95%CI) IFN +874 (A/T) High 0(0) - - - 7 (29,16) 0,027 2,97 0,80 - 10,41 9(12,16) Interm diate 19 (73,07) 0,009 3,19 1,10 - 10,008 13(54,16) 0,244 1,39 - 34(45,94) Low 7 (26,92) 0,095 0,51 - 4 (16,66) 0,013 0,28 0,063 - 0,95 31(41,89) TNF -308 (G/A) High 12 (46.15) 0.027 2.48 0.87 - 6.92 11(45.83) 0.032 2.45 0,83 - 7.05 19(25.68) Low 14 (53.85) 0.027 0.40 0.14 - 1.14 13(54.16) 0.032 0,41 0,14 - 1.20 55(74.32) IL-6 -174 (G/C) High 24 (92,30) 0,056 0,16 - 24 (100) 0,561 - 73(98,65) Low 2 (7,7) 0,056 6,08 - 0 / / / 1(1,35) IL-10 High 2 (7.69) 0.003 0.15 - 5 (20.8) 0,106 0,49 - 26(35.14) Low 7 (26.93) 0.048 0 .43 - 4 (16.7) 0,292 0,67 - 34(45.95) Intermediate 17 (65.38) 9.6.10 -6 8.10 - 15(62.5) 4.4.10 -4 7,14 - 14(18.92) TGF- 1 Low 1 (3.846) 1.410 -13 0,01 0.000 - 0.065 2 (8.333) 0 0,02 0.002 - 0.099 61(82,43) Intermediate 10 (38.462) 4.010 -6 22,50 4.052 - 220.742 5 (20.833) 0.003 9,74 1.376 - 103.584 2(2,7) High 15 (57.692) 2.010 -5 7,81 2.544 - 24.136 17 (70.833) 0 13,91 4.167 - 48.219 11(14,86) While the results showed significantly higher frequency respectively in T1D and LADA versus control for IL-10 -1082 A/G) G/A genotype (65. 38% vs . 45.95, Pc = 0.046, OR = 2.22) and IL-10 -592 (C/A) C allele (84% vs . 68.92%. Pc = 0.03, OR = 2.24) with intermediated profile (65.38% vs . 18.92 % Pc = 9.6.10 -6 OR = 8.10), (62.5% vs . 18.92 % Pc = 4.4.10 -6 OR = 7.14) and the results showed significantly higher frequency of TGF- 1 +869 TT genotype (50% vs . 22.97%, Pc = 6.8 10 -3 , OR = 3.36) and low secretion profile (45.83% vs . 25.68%, pc = 0.032, OR = 2.45) only in T1D vs. controls. The variants of interleukin IL-6 -174 G/C, l IL-10 -819 , TGF- 1 +915 (G/C) polymorphic genotypes or alleles ( P > 0.05) did not show a significant difference between patients and controls. Discussion In our study, we investigated the association between the T1DM and of IFN +874 (A/T), TNF -308 (G/A), IL-6 -174 G/C, l IL-10 -1082 A/G, -819 (C/T) -592 C/A), TGF- 1 +869 (T/C) +915 polymorphisms in T1D and LADA. Our results indicate that the of IFN +874 T allele and of TNF -308 A allele are associated with a T1D and LADA. The polymorphism effects of TNF and TNF on the risk of T1D have been reported in several other studies [18,19] . In the Korean population suggested that genetic effects of TNF gene polymorphisms on the risk of T1D might not be totally dependent on HLA genes [20] . We especially focused on TNF -308 (G/A), which is particularly interesting because of its known involvement in the differential transcriptional activator [21] . Also the aberrant expression of MHC class II molecules by non-immune cells has been described in patients with in T1D patients on pancreatic cells [22,23] . IFN- can induce the aberrant expression of HLA-DR as well as DP and DQ antigens on thyrocytes in vitro and human pancreatic islet cells [24,25] . IFN- , are also able to induce MHC antigen up-regulation and the expression of adhesion molecules by target cells, which overall can promote the activation of an autoimmune response [26] . Similar results have been reported from patients with T1D of Hungarian origin and Latvians [27,28] . We suppose that in these cases, higher TNF production associated with the position -308 G/A genotype in Langerhans islets, suggests that the autoimmune Th1 responses in T1D are probably TNF- mediated and low production in control have a protective effect against the autoimmune process and might delay the destruction of the b-cells We found no significant difference in IL-6 -174 G/C frequency between patients and their healthy control counter parts. This can be translated as an absence of association of IL-6 -174 G/C polymorphism to Algerian T1D and LADA patients. Our result is in total contrast with previous reports. In fact, a higher prevalence of IL-6 -174 GG genotype was reported in UK Caucasoid T1D patients [29] . In another study of Danish T1D families, IL-6 -174 C allele was associated with T1D only in females [30] . Herman et al (2005) reported that IL-6 -174 G was associated with older age onset of T1D in the presence of high cytokine producer IL-1 and TNF- genotypes [31] . We have found significant difference of genotype and alleles frequencies among T1D and LADA respectively compared to controls for gene polymorphism at position l IL-10 -1082 and l IL-10 -592 (C/T). Our results agreement with that reported by Reynier et al. with lack of association of IL-10 promoter gene variants with type 1 diabetes in a French population and Urcelay and al in Spanish population [32,33] . The frequency of low producer haplotype of IL-10 ATA haplotype with positions -1082 (A/G), -819 (C/T) -592 (C/A) has been shown to be increased in the patients with adult-onset diabetes in Japan [34] . IL-10 has been shown to hyperinduce ICAM-1 expression on vascular endothelium where pancreatic and to drive pathogenic autoimmune responses and accelerated diabetes through an ICAM-1-dependent pathway [35] . Regarding TGF- 1 gene no significant difference was observed between LADA patients and controls position +869 (T/C), +915 (G/C). Kumar et al. 2007 demonstrated that a significant increase in high producer haplotypes of TGF- 1 with TNF -308 GA/AA in the patients with T1D compared with the controls were observed [36] . The TGF- 1 has been shown to be an extremely potent chemotactic factor in vitro , which influences monocyte recruitment and accumulation by increased expression of and -integrins [37] . Increased levels of TGF- 1 have been associated with destruction of pancreatic beta cells and pathogenesis of diabetic complications [38] . Hence, in the presence of high secretors of TNF- , the high secretor genotypes of TGF- 1 may have a role both in destruction of pancreatic beta cells and in migration of CD4+ and CD8+ T cells into the pancreas [39] . Conclusion We conclude that additional genetic predisposition to T1D and LADA; these results suggest that the secretion low of IFN- and high secretion of TNF- may play an important role in protection and susceptibility to autoimmune diabetes in the Algerian population. Because TNF- , IFN and IL10 showed a significant association with T1D and LADA, we wanted to study whether simultaneous presence of TNF- genotypes with different genotypes of the other cytokines in an individual could suggest an interaction between these cytokine genes. Authors contributions RR, AH, EM, conceived and designed the study and collected the data, MA, AB selection of patients, CTB, MCA and NA wrote the manuscript. All authors read and approved the final manuscript. Consent for publication: All authors have reviewed the final version of the manuscript and approve it for publications. Ethics approval and consent to participate: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (ATRSS-USTHB-ALGERIA) and with the Helsinki Declaration of 1975, as revised in 2008. All the patients signed the consent form for allowing their information to be used for research. Abbreviations: IFN : Interferon Gamma; TNF : Tumor Necrosis Factor Alpha; IL- 6: Interleukin 6, l IL-10: Interleukin 10, TGF- 1: Transforming Growth Factor Beta, T1D: Type 1 diabetes, LADA: Latent Autoimmune Diabetes in Adults (LADA), PCRSSP: Polymeras Chain Reaction Sequence Specific Primers, DNA: Deoxyribonucleic Acid. Acknowledge: This study was supported by the laboratory of immunopathology and immunogenetique (LIGIP), Alger, Algeria. Competing interest: The authors declare that they have no competing interests. Availability of data and materials. The data used in the analysis are clearly and precisely documented and are readily available to any researcher for purposes of replication. References 1. Turner, R., Stratton, I., Horton, V., et al. Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. (1997) Lancet 350(9087): 1288-1293. Pubmed || Crossref || Others 2. Borchers, A.T., Uibo, R., Gershwin, M.E. The geoepidemiology of type 1 diabetes. (2010) Autoimmun Rev 9(5): A355 A365. Pubmed || Crossref || Others 3. Cucca, F., Lampis, R., Congia, M., et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. (2001) Hum Mol Genet 10(19): 2025-2037. Pubmed || Crossref || Others 4. Bell, G.I., Horita, S., Karam, J.H., et al. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. (1984) Diabetes 33(2): 176-183. Pubmed || Crossref || Others 5. Bottini, N., Musumeci, L., Alonso, A., et al. A functional variant of lymphoid tyrosine Phosphatase is associated with type I diabetes. (2004) Nat Genet Apr 36(4): 337-338. Pubmed || Crossref || Others 6. Dahlen, E., Dawe, K., Ohlsson, L., et al. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. (1998) J Immunol. Apr 1:160(7): 3585-3593. Pubmed || Crossref || Others 7. Stephens, L.A., Thomas, H.E., Ming, L., et al. Tumour necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. (1999)Endocrinology Jul; 140(7): 3219-3227. Pubmed || Crossref || Others 8. Wastowski, I.J., Peres, N.T., Simoes, R.T., et al. Identification of a novel 120 bp allele at the TNFD microsatellite locus. (2006) Tissue Antigens Apr 67(4): 318 320. Pubmed || Crossref || Others 9. Hajeer, A.H., Hutchinson, I.V., et al. Influence of TNF alpha gene polymorphisms on TNF alpha production and disease. (2001)Hum Immunol. Nov 62(11): 1191 1199. Pubmed || Crossref || Others 10. Fishman, D., Faulds, G., Jeffery, R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. (1998) J Clin Invest Oct 1:102(7): 1369-1376. Pubmed || Crossref || Others 11. Hawrylowicz, C.M., & O' Garra, A., et al. Potential role of interleukin 10 secreting regulatory T cells in allergy and asthma. (2005) Nat Rev Immunol Apr, 5(4): 271 283. Pubmed || Crossref || Others 12. Tripp , CS., Wolf, SF., Unanue, ER ., et al .Interleukin 12 and tumour necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. (1993) Proc Natl Acad Sci USA Apr 15: 90(8): 3725 3729. Pubmed || Crossref || Others 13. Eskdale, J., Gallagher, G., et al. A polymorphic dinucleotide repeat in the human IL-10 promoter. (1995) Immunogenetics 42(5): 444-445. Pubmed || Crossref || Others 14. Yu, L., Yang, MS., Zhao, J., et al. An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. (2004) Schizophr Res Nov 1:71(1): 179-183. Pubmed || Crossref || Others 15. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. (1979) Diabetes Dec; 28(12): 1039-1057. Pubmed || Crossref || Others 16. Ahmad, N.N., Cu-Cujieng., A.B, Donosala. L.A., et al. Modification of standard proteinase K/ phenol method for DNA isolation to improve yield and purity from frozen blood. (1995) J Med Genet Feb; 32(2): 129-130. Pubmed || Crossref || Others 17. Woolf, B. On estimating the relation between blood group and disease. (1955) Ann Hum Genet Jun;(19)4: 251-253. Pubmed || Crossref || Others 18. Hamaquchi, K., Kimura, A., Seki, N., et al. Analysis of tumour necrosis factor-alpha promoter polymorphism in type 1 diabetes: HLA-B and -DRB1 alleles are primarily associated with the disease in Japanese. (2000) Tissue Antigens Jan; 55(1): 10-16. Pubmed || Crossref || Others 19. Bouqbis, L., Akhayat, O., Garchon, H.J., et al. TNFA-TNFB haplotypes modify susceptibility to type I diabetes mellitus independently of HLA class II in a Moroccan population.(2003) Tissue Antigens Jan; 61(1): 72 79. Pubmed || Crossref || Others 20. Deng, G.Y., Maclaren, N.K., Huang, H.S., et al. No primary association between the 308 polymorphism in the tumour necrosis factor alpha promoter region and insulin-dependent diabetes mellitus. (1996) Hum Immunol Feb; 45(2): 137-142. Pubmed || Crossref || Others 21. Shin, H D., Yang, SW, Kim, D.H., Park, Y., et al. Independent Association of Tumour Necrosis Factor Polymorphism with Type 1 Diabetes Susceptibility. (2008) Immunology of Diabetes: Ann. N.Y. Acad. Sci. Dec; 1150: 76 85. Pubmed || Crossref || Others 22. Bottazzo, G.F., Dean, B.M., McNally, J.M., et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. (1985) New Eng J Med Aug; 313(6): 353-360. Pubmed || Crossref || Others 23. Foulis, A.K., Farquharson, M.A., Hardman, R., et al. Aberrant expression of Class II major histocompatibility complex molecules by B cells and hyper expression of Class I major histocompatibility complex molecules by insulin containing islets in Type 1 (insulin-dependent) diabetes mellitus. (1987) Diabetologia May; 30(5): 333- 343. Pubmed || Crossref || Others 24. Todd, I., Pujol-Borrell, R., Hammond, L.J., et al. Interferon-gamma indices HLA-DR expression by thyroid epithelium. (1985) Clin Exp Immunol Aug; 61(2): 265-273 Pubmed || Crossref || Others 25. Pujol-Borrel, R., Todd, I., Doshi, M., et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987; 326: 304-6 Pubmed || Crossref || Others 26. Campbell, I.L., Cutri, A., Wilkinson, D., et al. Intercellular adhesion molecule 1 is induced on isolated endocrine islet cells by cytokines but not by reovirous infection. (1989) Proc Natl Acad Sci USA Jun; 86(11): 4282-6. Pubmed || Crossref || Others 27. Krikovszky, D., Vasarhelyi, B., Toth-Heyn, P., et al. Association between G-308A polymorphism of the tumour necrosis factor alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. (2002) Clin Genet Dec; 62(6): 474-477. Pubmed || Crossref || Others 28. Shtauvere-Brameus, A., Dabadghao, P., et al. Tumour necrosis factor alpha allele 2 shows an association with insulin dependent diabetes mellitus in Latvians.(2002)Ann N Y Acad Sci Apr; 958: 357 61. Pubmed || Crossref || Others 29. Jahromi, M.M., Millward, B.A., Demaine, A.G., et al. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. (2000) J Interferon Cytokine Res Oct; 20(10):885-888. Pubmed || Crossref || Others 30. Kristiansen, O.P., and Mandrup-Poulsen, T., et al. Interleukin-6 and diabetes: the good, the bad, or the Indifferent? (2005) Diabetes Dec ;54 Suupl 2: S114-S124 Pubmed || Crossref || Others 31. Herman, C., Krikovszky, D., F st, G., et al. Association between interleukin-6 polymorphism and age-at-onset of type 1 diabetes. Epistatic influences of the tumour necrosis factor-A and interleukin-1b polymorphisms. (2005) Eur Cytokine Netw. Dec; 16 (4): 277-81. Pubmed || Crossref || Others 32. Reynier, F., Cazalis, M.A., Lecoq, A., et al. Lack of association of IL-10 promoter gene variants with type 1 diabetes in a French population.(2006) Hum Immunol Apr-May; 67(4 5):311 317. Pubmed || Crossref || Others 33. Urcelay, E., Santiago, JL., de la Calle, H., et al. Interleukin-10 polymorphisms in Spanish patients.(2004) Genes and Immunity Jun; 5(4): 306-309 Pubmed || Crossref || Others 34. Ide, A., Kawasaki, E., Abiru, N., et al. Genetic association between interleukin-10 gene promoter region polymorphism and type 1 diabetes age-at-onset. (2002)Hum Immunol Aug; 63(8): 690-5 Pubmed || Crossref || Others 35. Balasa, B., La Cava, A., Van Gunst, K., et al. A mechanism for IL-10 mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. (2000)J Immunol Dec 15:1 65(12): 7330-7. Pubmed || Crossref || Others 36. Kumar, R., Goswami, R., Agarwal, R., et al. Association and interaction of the TNF-alpha gene with other pro- and anti-inflammatory cytokine genes and HLA genes in patients with type 1 diabetes from North India. (2007) Tissue Antigens Jun 69(6): 557-67. Pubmed || Crossref || Others 37. Wahl, SM., Allen, JB., Weeks, B.S., et al. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. (19993) Proc Natl Acad Sci U S A May 15;90(10): 4577-81 Pubmed || Crossref || Others 38. Korpinen, E., Groop, P.H., Fagerudd, J.A., et al. Increased secretion of TGF-b1 by peripheral blood mononuclear cells from patients with, Type 1 diabetes mellitus with diabetic nephropathy. (2001) Diabet Med Feb: 18(2): 121-125. Pubmed || Crossref || Others 39. Eerligh, P., Koeleman, B.P., Dudbridge, F., et.al. Functional genetic polymorphisms in type 1 diabetes. (2004) J clinical investigation 113(3): 451-463. Pubmed || Crossref || Others